Evidence map›Paper›PMID 41592280›Full record

ArticleBlood advances2026

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Sita Bhella, Gerard Agbayani, Katrina Hueniken, Abi Vijenthira, Allison M Wilkin, Michael Sebag, Peng Wang, Lisa K Hicks, Annette E Hay, Seyed M Hosseini-Moghaddam and 35 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Sita BhellaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Gerard AgbayaniOttawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-1207-9858
Katrina HuenikenDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Abi VijenthiraDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Allison M WilkinOttawa Hospital Research Institute, Ottawa, ON, Canada.
Michael SebagMcGill University Health Centre, Montreal, QC, Canada.
Peng WangDepartment of Medicine, University of Alberta, Edmonton, AB, Canada.
Lisa K HicksDivision of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-1858-7420
Annette E HayDivision of Hematology, Kingston Health Sciences Centre, Queen's University, Kingston, ON, Canada.ORCID 0000-0003-4581-3390
Seyed M Hosseini-MoghaddamTransplant Infectious Diseases and Ajmera Transplant Centre, University Health Network, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-7979-2458
Sarit AssoulineDivision of Hematology, Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0002-7638-1589
Amaris BalitskyDivision of Hematology, Hamilton Health Sciences Juravinski Cancer Centre, Hamilton, ON, Canada.
Graeme FraserDivision of Hematology, Hamilton Health Sciences Juravinski Cancer Centre, Hamilton, ON, Canada.
Joy MangelDivision of Hematology, Department of Medicine, Schulich School of Medicine & Dentistry, London, ON, Canada.
Carolyn OwenDivision of Hematology and Hematologic Malignancies, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Anthony ReimanDepartment of Oncology, Saint John Regional Hospital, Saint John, NB, Canada.
Laurie SehnBC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, BC, Canada.
Heather SutherlandLeukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, BC Cancer, The University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-8872-1934
Corey ArnoldDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Arleigh McCurdyOttawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-8809-4368
Donna ReeceDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.ORCID 0009-0002-9686-4323
Tamara LeiteOttawa Hospital Research Institute, Ottawa, ON, Canada.
Erinn McCarthyDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Curtis CooperOttawa Hospital Research Institute, Ottawa, ON, Canada.
Angela M CrawleyOttawa Hospital Research Institute, Ottawa, ON, Canada.
Marc-André LangloisDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0003-4652-3029
C Arianne BuchanOttawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0003-3617-3213
David Allan
Andrew Aw
Stephen Betschel
Shelly Bolotin
Joseph Brandwein
Christopher Bredeson
James Brooks
Matthew Cheung
Michael Chu
Vikas Gupta
Natasha Kekre
Deepali Kumar
Caroline Moltzan
Anca Prica
Julie Stakiw
Alissa Wright
Tara Baetz
Jill Dudebout

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractPlasma cell dyscrasias (PCD) are a group of hematologic disorders associated with immune dysfunction from underlying disease and/or treatment. With the continued circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), optimizing and maintaining durable protection in this vulnerable population through vaccination remains important. A prospective cohort study was conducted between August 2021 and January 2023 across 12 sites in Canada to evaluate humoral immunity to COVID-19 vaccination in participants with hematologic malignancies. Participants were monitored longitudinally, and finger-prick dried blood spot cards were obtained at specific intervals based on vaccination. Serum antibodies against SARS-CoV-2 proteins after the third, fourth, and fifth dose were measured by high-throughput enzyme-linked immunosorbent assay. Differences in antispike (anti-S) seropositivity by vaccine dose number and clinical risk factors were analyzed by logistic regression. A total of 262 unique participants with 983 samples were included for analysis, among which 66% were diagnosed with PCD. Analysis of the predicted probability of immunity showed consistently higher proportions of participants with PCD with vaccine (anti-S) immunity compared with those with infection-derived (antinucleocapsid) immunity throughout the study. Although vaccine responses appeared to wane 6 months after dose 3 and, to a lesser extent, after dose 4, subsequent doses cumulatively increased anti-S immunity. Seropositivity decreased with anti-CD38 therapy and older age, although the receipt of additional vaccine doses significantly improved anti-S immunity. Overall, this study demonstrated that the third and subsequent COVID-19 vaccine doses could safely improve humoral immunity in participants with PCD. Although anti-CD38 therapy and age reduced seropositivity, antibody responses could still be enhanced with vaccine doses beyond the primary 3-dose series.

Indexed as

COVID-19COVID-19 VaccinesImmunogenicity, VaccineParaproteinemiasSARS-CoV-2AdultAgedAntibodies, ViralFemaleHumansImmunity, HumoralMaleMiddle AgedProspective StudiesVaccinationAntibodies, ViralCOVID-19 Vaccines

Identifiers

PMID41592280
PMCPMC13138197

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.